Hypertension in adults (update) Committee meeting

Date: 07/06/2018

Location: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE

Minutes: Confirmed

Committee members present:

Anthony Wierzbicki (Chair) (Present for notes 1–5)
Liz Clark (Present for notes 1–5)
Mark Glover (Present for notes 1–5)
Judith Magowan (Present for notes 1–5)
Irene McGill (Present for notes 1–5)
Lucy Pollock (Present for notes 1–5)
Mark Shapley (Present for notes 1–5)

Co-opted member

Parijat De (Present for notes 1–5)

In attendance:

Caroline Kier Guideline Commissioning Manager, NICE (Present for notes 1–5)
Rebecca Boffa Senior Research Fellow, NGC (Present for notes 1–5)
Serena Carville Guideline Lead, NGC (Present for notes 1–5)
Margaret Constanti Senior Health Economist, NGC (Present for notes 1–5)
Meredith Faust Project Manager, NGC (Present for notes 1–5)
Christopher Floyd Clinical Trainee, NGC (Present for notes 1–5)
Audrius Stonkus Trainee Research Fellow, NGC (Present for notes 1–5)
Rafina Yarde Research Fellow, NGC (Present for notes 1–5)

Apologies:

Elizabeth Denver Committee member
1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the eighth meeting of Hypertension in adults. The committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included second-, third-, and fourth-line drug sequencing reviews.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was second-, third-, and fourth-line drug sequencing.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role with NICE</th>
<th>Type of interest</th>
<th>Description of interest</th>
<th>Relevant dates</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parija t De</td>
<td>Co-opted committee member</td>
<td>Direct financial</td>
<td>I have received speaker fees for educational talks in diabetes from most companies but not from any pharmaceutical companies regarding hypertension</td>
<td>Interest arose</td>
<td>Upon appointment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Interest declared</td>
<td></td>
</tr>
</tbody>
</table>
The Chair and a senior member of the Developer’s team noted that the interests previously declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Questions and discussion

A. The Chair reviewed the included and excluded populations for the guideline. The committee asked questions.

B. Rafina Yarde, Research Fellow at the NGC, presented the evidence for the review question ‘What is the most clinically and cost-effective sequence for second- and third-line treatment for hypertension?’ The committee discussed and asked questions about the clinical evidence and drafted recommendations.

C. Audrius Stonkus, Trainee Research Fellow at the NGC, presented the evidence for the review question ‘What is the most clinically and cost-effective sequence for fourth-line treatment for hypertension?’ The committee discussed and asked questions about the clinical evidence and drafted recommendations.

D. The committee discussed the recommendations and write-up for review question 1.1: In people with suspected hypertension, which test is most accurate in identifying whether hypertension is present, as indicated by the reference standard, ambulatory blood pressure measurement?

E. The committee discussed the recommendations and write-up for review question 5.1: What is the clinical and cost-effectiveness of relaxation therapies for the management of primary hypertension in adults?

5. Any other business

None.
Date of next meeting: 11/07/2018

Location of next meeting: NGC Boardroom, Royal College of Physicians, 11 St Andrew’s Place, London NW1 4LE